Business
Agenus First Quarter Results and Update
- AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1 - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26%
About this update from Agenus Inc.
[{"type":"text","content":"- AGEN1181 (nextgen CTLA-4) +/- balstilimab (anti-PD-1) shows benefit in 70% of patients in Phase 1\n - Balstilimab + Zalifrelimab (anti-CTLA-4) achieve 26% response rates in a cohort of 55 patients with advanced cervical cancer\n - Two INDs filed for AgenTus cell therapy (Allogeneic iNKTs) for cancer & COVID-19\n - Two TIGIT antibodies advancing; IND filings starting in Q4\n - Recent organizational streamlining expected to reduce annualized burn by $50M\n\n\nLEXINGTON, Mass., May 7, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and reported financial results for the first quarter of 2020.\n\"We accelerated the development of AGEN1181, advanced our plans to file our BLAs and filed two INDs for our allogeneic iNKT cell therapy to treat cancer and COVID-19,\" said Garo Armen, Ph.D., Chairman and CEO, Agenus. \"Our ability to rapidly enroll in our bali and zali trials, in just 2 years, underscores the speed with which we can advance our AGEN1181 +/- bali and our innovative pipeline of products including allogeneic cell therapy programs.\" \nAGEN1181, reveals clinical benefit1 in >70% of response-evaluable patientsEarly data suggest that AGEN1181 could be a breakthrough in IO treatment: Confirmed CR with AGEN1181 (1 mg/kg) in advanced endometrial cancer with a poor prognosis Confirmed PR (significant tumor reduction) in advanced endometrial cancer with low-dose AGEN1181 + balstilimab Disease stabilization in the majority of response-evaluable patients Advisory board endorsed accelerated plans for AGEN1181 development \nBalstilimab & zalifrelimab demonstrate ~26% response rates which are durable in an all-comer, non-biomarker selected population Large cohort analysis (n=55) bali + zali demonstrate ~26% response rates (4 CRs, 10 PRs) in refractory cervical cancer Responses are durable over 12 months \nAllogeneic iNKTs advancing to clinic for the treatment of cancer and COVID-19 COVID-19: iNKTs designed to eliminate COVID-19 virus, dampen harmful inflammation, and promote protection from reinfection (FIM 1H2020) CANCER: iNKTs designed to promote anti-tumor immunity in cancer & enable optimal combinations with Agenus checkpoint antibodies \nPotential best and first in class TIGIT programs advanci...